Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Allen

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2000
Diagnosis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients with polymerase chain reaction: a blinded comparison to standard methodsJ Torres, M Goldman, L J Wheat, et al.
Annals of the New York Academy of Sciences|January 1, 1988
Substituted 5-phenoxyalkyl-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2- methylisoxazolidines. Antifungal activity and structure-activity relationship studiesG B Mullen, D M Maryniak, P A Swift, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 1993
In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolatesS A Marshall, R N Jones, P R Murray, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 1, 1988
In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101A L Barry, K E Aldridge, S D Allen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
In vitro antifungal activity of novel substituted 3,5-diphenyl-3-(1H-1,2,4-triazol-1-ylmethyl)-2- methylisoxazolidine derivativesG A Bennett, P A Swift, G B Mullen, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1989
Multicenter in vitro evaluation of SM-7338, a new carbapenemR N Jones, K E Aldridge, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|August 1, 1993
In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centersH S Sader, R N Jones, J A Washington, et al.
Journal of Clinical Microbiology|March 1, 1993
Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized testsA L Barry, P C Fuchs, J H Jorgensen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
cis-3-(substituted phenyl)-3-(1H-imidazol-1-ylmethyl)-2-methyl-5-([(substituted phenyl)thio(or amino)]methyl)isoxazolidines. In vitro antifungal activity and structure-activity relationshipsT R DeCory, P A Swift, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
3-(substituted phenyl)-3-(1H-1,2,4-triazol-1-ylmethyl)-2-methyl-5- [(substituted phenoxy)methyl]-isoxazolidine derivatives. Structure-activity relationshipsG A Bennett, P A Swift, G B Mullen, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2000
Diagnosis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients with polymerase chain reaction: a blinded comparison to standard methodsJ Torres, M Goldman, L J Wheat, et al.
Annals of the New York Academy of Sciences|January 1, 1988
Substituted 5-phenoxyalkyl-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2- methylisoxazolidines. Antifungal activity and structure-activity relationship studiesG B Mullen, D M Maryniak, P A Swift, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 1993
In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolatesS A Marshall, R N Jones, P R Murray, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 1, 1988
In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101A L Barry, K E Aldridge, S D Allen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
In vitro antifungal activity of novel substituted 3,5-diphenyl-3-(1H-1,2,4-triazol-1-ylmethyl)-2- methylisoxazolidine derivativesG A Bennett, P A Swift, G B Mullen, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1989
Multicenter in vitro evaluation of SM-7338, a new carbapenemR N Jones, K E Aldridge, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|August 1, 1993
In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centersH S Sader, R N Jones, J A Washington, et al.
Journal of Clinical Microbiology|March 1, 1993
Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized testsA L Barry, P C Fuchs, J H Jorgensen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
cis-3-(substituted phenyl)-3-(1H-imidazol-1-ylmethyl)-2-methyl-5-([(substituted phenyl)thio(or amino)]methyl)isoxazolidines. In vitro antifungal activity and structure-activity relationshipsT R DeCory, P A Swift, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
3-(substituted phenyl)-3-(1H-1,2,4-triazol-1-ylmethyl)-2-methyl-5- [(substituted phenoxy)methyl]-isoxazolidine derivatives. Structure-activity relationshipsG A Bennett, P A Swift, G B Mullen, et al.
Pageof 15